Fed. Circ. Nixes Apotex Appeal In Taxotere IP Fight
In granting Sanofi's motion to dismiss the cross-appeal, a three-judge panel of the U.S. Court of Appeals for the Federal Circuit ruled that Apotex's cross-appeal was improper because, if successful, it would not expand the scope of the judgment in Apotex's favor.
While Apotex may raise these arguments in its appellees' brief, it cannot...
To view the full article, register now.